BIO10870-T1

NGAL as a novel target for the treatment of Chronic Kidney Disease

The severity of renal lesions after nephron reduction varied substantially among mouse strains and required activation of EGFR. Lipocalin 2 (Lcn2, also known as neutrophil gelatinase–associated lipocalin [NGAL]), the most highly upregulated gene in a mouse strain which develop severe renal lesions, is not simply a marker of renal lesions, but also an active player in disease progression. The severity of renal lesions was dramatically reduced in Lcn2–/– mice. Lcn2 expression increases upon EGFR activation and Lcn2 mediates its mitogenic effect during renal deterioration. EGFR inhibition prevented Lcn2 upregulation and lesion development in mice expressing a dominant negative EGFR isoform. Cell proliferation was dramatically reduced in Lcn2–/–mice. LCN2 is increased particularly in patients who rapidly progressed to end-stage renal failure. (Viau A. et al., J Clin Invest. 2010 Nov;120(11):4065-76. doi: 10.1172/JCI42004.)


Keywords : Nephrology, Diagnostics, Biomarker, Chronic Kidne
Patent Application number : EP10306077.8
Patent Application date : 2010-10-01
Multidisciplinary field : Fibrosis
Technology/Engineering : -
Technological Platform : -
Rare disease : -
Second indication : -
Inventors : Martine BURTIN
Khalil EL KAROUI
Fabiola TERZI
Amandine VIAU
Clément NGUYEN
Publications :
  • Viau et al, 2010 The Journal of Clinical Investiga

Related offers


The 10 Last viewed

You haven't seen any form yet.